Twist Bioscience Stock Forecast, Price & News

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TWST shares have increased by 589.8% and is now trading at $194.53.
View which stocks have been most impacted by COVID-19.

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Twist Bioscience stock.
View analyst ratings for Twist Bioscience or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Twist Bioscience a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Twist Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,448 employees have rated Twist Bioscience CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Twist Bioscience's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Twist Bioscience.

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings data on Sunday, November, 22nd. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.16. The business earned $32.43 million during the quarter, compared to analyst estimates of $22.70 million. Twist Bioscience had a negative net margin of 155.31% and a negative return on equity of 44.62%.
View Twist Bioscience's earnings history.

Twist Bioscience issued an update on its FY 2021 Pre-Market earnings guidance on Monday, November, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $110-118 million, compared to the consensus revenue estimate of $117.94 million.

4 brokers have issued 1-year target prices for Twist Bioscience's shares. Their forecasts range from $42.00 to $125.00. On average, they anticipate Twist Bioscience's share price to reach $89.00 in the next twelve months. This suggests that the stock has a possible downside of 54.2%.
View analysts' price targets for Twist Bioscience or view Wall Street analyst' top-rated stocks.

Twist Bioscience saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 2,920,000 shares, a drop of 20.0% from the December 15th total of 3,650,000 shares. Based on an average daily trading volume, of 643,800 shares, the days-to-cover ratio is presently 4.5 days.
View Twist Bioscience's Short Interest.

Some companies that are related to Twist Bioscience include Seagen (SGEN), BioNTech (BNTX), Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Fate Therapeutics (FATE), Novavax (NVAX), Acceleron Pharma (XLRN) and Iovance Biotherapeutics (IOVA).
View all of TWST's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green and William Banyai.
View institutional ownership trends for Twist Bioscience.

TWST stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green, and William Banyai.
View insider buying and selling activity for Twist Bioscience or view top insider-selling stocks.

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TWST stock can currently be purchased for approximately $194.53.

Twist Bioscience has a market capitalization of $9.46 billion and generates $90.10 million in revenue each year. The company earns $-139,930,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis. Twist Bioscience employs 525 workers across the globe.

The official website for Twist Bioscience is www.twistbioscience.com.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]